Market Overview

UPDATE: Egalet's Egalet-002 Was Well Tolerated, Phase 3 Trial Remains On Track For Completion By Year-End

Share:

Get News First. Profit Faster

upsell-button
With Benzinga Professional get unlimited access to ALL content! PLUS:
  • REALTIME NEWSFEED
  • REALTIME AUDIO NEWS
  • FULL CALENDAR SUITE
  • CHAT WITH OUR NEWS DESK

Posted-In: Biotech News General

 

Related Articles (EGLT)

Partner Center